|
Indications and Dosage
Oral
Peripheral vascular disease, Prophylaxis of migraine Adult: 5-10 mg daily in the evening.
|
|
Administration
May be taken with or without food.
|
|
Contraindications
History of depression, pre-existing symptoms of Parkinson’s disease, other extrapyramidal disorders.
|
|
Special Precautions
Not indicated for acute migraine attacks. Hepatic impairment. Elderly
|
|
Adverse Reactions
Significant: Depression, extrapyramidal symptoms; mild increase in serum prolactin levels and menstrual irregularities. Rarely, galactorrhoea.
Gastrointestinal disorders: Dry mouth, nausea, vomiting, stomach pain. Investigations: Weight gain. Metabolism and nutrition disorders: Increased appetite. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Drowsiness, dizziness. Psychiatric disorders: Insomnia. Skin and subcutaneous tissue disorders: Rash. |
|
Patient Counseling Information
This drug may cause CNS depression, if affected, do not drive or operate machinery.
|
|
Monitoring Parameters
Monitor for signs and symptoms of depression, and extrapyramidal symptoms.
|
|
Drug Interactions
Increased risk of excessive sedation with CNS depressants. May increase therapeutic effects of antihypertensive drugs. May increase the risk of galactorrhoea with oral contraceptives.
|
|
Food Interaction
Increased risk of excessive sedation with alcohol.
|
|
Action
Description:
Mechanism of Action: Flunarizine is a difluorinated derivative of cinnarizine. It is a selective Ca channel blocker that decreases excessive transmembrane Ca influx thus preventing cellular Ca overload. It also has antihistamine, and sedative properties. Pharmacokinetics: Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: 2-4 hours. Distribution: Volume of distribution: 43.2 L/kg. Plasma protein binding: >90%. Metabolism: Extensively metabolised in the liver via N-oxidation and aromatic hydroxylation. Excretion: Via faeces (<6% at 48 hours); urine (minimal). Elimination half-life: Approx 18 days. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 941361, Flunarizine. https://pubchem.ncbi.nlm.nih.gov/compound/941361. Accessed Aug. 26, 2022. |
|
Storage
Store below 30°C. Protect from light and moisture.
|
|
MIMS Class
|
|
ATC Classification
N07CA03 - flunarizine ; Belongs to the class of antivertigo preparations.
|
|
References
Anon. Flunarizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/08/2022. Buckingham R (ed). Flunarizine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/08/2022. Fludan Capsules (Medispec [M] Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/08/2022. Flumig 5 mg Capsule (Justright Pharmaceuticals). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/08/2022. Forknow Tablet (Y.S.P. Industries [M] Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/08/2022. Vanid (Unison Laboratories Co Ltd [HK]). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 04/08/2022.
|
Sign Out
